Use of Incretin Agents and Risk of Pancreatic Cancer: A Population-Based Cohort Study.

CONCLUSIONS: We found that incretin use was not associated with pancreatic cancer after adjustment for the severity of the underlying T2DM. The elevated risk of pancreatic cancer in recent starters of incretin agents is likely to be caused by protopathic bias or other types of unknown distortion. The presence of considerable confounding by disease severity and the lack of duration of use relationship do not support a causal explanation for the association between incretin agents and pancreatic cancer.
PMID: 26537555 [PubMed - as supplied by publisher]

Source: Diabetes Metab - November 5, 2015 Category: Endocrinology Authors: Knapen LM, van Dalem J, Keulemans YC, van Erp NP, Bazelier MT, De Bruin ML, Leufkens HG, Croes S, Neef C, de Vries F, Driessen JH Tags: Diabetes Obes Metab Source Type: research